The Asia Pacific Computational Pathology Market is expected to witness market growth of 8.5% CAGR during the forecast period (2025-2032).
The China market dominated the Asia Pacific Computational Pathology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $90.2 million by 2032. The Japan market is registering a CAGR of 8.1% during 2025-2032. Additionally, the India market is expected to showcase a CAGR of 9.8% during 2025-2032.
This pathology is also being used to study diseases of the nervous system, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. By analyzing brain tissue samples, computational tools can identify characteristic patterns of neurodegeneration, helping doctors diagnose and monitor these diseases' progression with a level of precision that was previously unattainable.
These pathology aids in diagnosing infections by analyzing tissue samples from infected patients. It allows for a more efficient identification of pathogens, such as bacteria, viruses, and fungi, in biopsy samples. This is particularly beneficial in cases where pathogens are difficult to identify through traditional methods. Another application of this pathology is cardiovascular disease diagnosis.
India’s hospital industry, which accounts for 80% of the total healthcare sector, is attracting significant investment from domestic and international players. With the healthcare industry expected to reach $132 billion by 2023, this investment surge is fuelling modernization efforts and encouraging the adoption of advanced diagnostic technologies. Computational pathology, with its ability to deliver faster and more precise diagnoses through AI-enabled analysis of pathology slides, is increasingly being integrated into hospitals and diagnostic centers. The push for digital transformation, a rising patient load, and a focus on early disease detection are making India a hotspot for computational pathology expansion. China’s pharmaceutical industry, valued at $161.8 billion in 2023 and accounting for about 30% of the global market, underscores the country’s pivotal role in global healthcare. The concurrent rise of the biotechnology sector is further accelerating the demand for cutting-edge diagnostic tools and platforms. In summary, India’s hospital expansion, China’s pharmaceutical dominance, and Japan’s aging demographic and tech-driven healthcare model collectively drive the market's rapid growth in Asia.
The China market dominated the Asia Pacific Computational Pathology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $90.2 million by 2032. The Japan market is registering a CAGR of 8.1% during 2025-2032. Additionally, the India market is expected to showcase a CAGR of 9.8% during 2025-2032.
This pathology is also being used to study diseases of the nervous system, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. By analyzing brain tissue samples, computational tools can identify characteristic patterns of neurodegeneration, helping doctors diagnose and monitor these diseases' progression with a level of precision that was previously unattainable.
These pathology aids in diagnosing infections by analyzing tissue samples from infected patients. It allows for a more efficient identification of pathogens, such as bacteria, viruses, and fungi, in biopsy samples. This is particularly beneficial in cases where pathogens are difficult to identify through traditional methods. Another application of this pathology is cardiovascular disease diagnosis.
India’s hospital industry, which accounts for 80% of the total healthcare sector, is attracting significant investment from domestic and international players. With the healthcare industry expected to reach $132 billion by 2023, this investment surge is fuelling modernization efforts and encouraging the adoption of advanced diagnostic technologies. Computational pathology, with its ability to deliver faster and more precise diagnoses through AI-enabled analysis of pathology slides, is increasingly being integrated into hospitals and diagnostic centers. The push for digital transformation, a rising patient load, and a focus on early disease detection are making India a hotspot for computational pathology expansion. China’s pharmaceutical industry, valued at $161.8 billion in 2023 and accounting for about 30% of the global market, underscores the country’s pivotal role in global healthcare. The concurrent rise of the biotechnology sector is further accelerating the demand for cutting-edge diagnostic tools and platforms. In summary, India’s hospital expansion, China’s pharmaceutical dominance, and Japan’s aging demographic and tech-driven healthcare model collectively drive the market's rapid growth in Asia.
List of Key Companies Profiled
- Koninklijke Philips N.V.
- F.Hoffmann-La Roche Ltd.
- PathAI, Inc.
- Hamamatsu Photonics K.K.
- Olympus Corporation
- Visiopharm A/S
- Mikroscan Technologies, Inc.
- MindPeak GmbH
- Indica Labs, LLC
- Nucleai, Inc. (Nucleai)
Market Report Segmentation
By Component
- Software
- Services
By Application
- Disease Diagnosis
- Drug Discovery & Development
- Academic Research
By End-use
- Hospitals and Diagnostic Labs
- Biotechnology & Pharmaceutical Companies
- Academic and Research Institutes
- Other End-use
By Technology
- Machine Learning (ML)
- Deep Learning
- Other Machine Learning (ML)
- Computer Vision
- Natural Language Processing (NLP) Models
- Other Technology
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Computational Pathology Market by Component
Chapter 6. Asia Pacific Computational Pathology Market by Application
Chapter 7. Asia Pacific Computational Pathology Market by End-use
Chapter 8. Asia Pacific Computational Pathology Market by Technology
Chapter 9. Asia Pacific Computational Pathology Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- F. Hoffmann-La Roche Ltd.
- PathAI, Inc.
- Hamamatsu Photonics K.K.
- Olympus Corporation
- Visiopharm A/S
- Mikroscan Technologies, Inc.
- MindPeak GmbH
- Indica Labs, LLC
- Nucleai, Inc. (Nucleai)
Methodology
LOADING...
